Medicare Enrolled
Dr. Indu Sharma, M.D.
Hematology & Oncology · Mahwah, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sharma from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sharma?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sharma
Dr. Indu Sharma is a hematology & oncology specialist in Mahwah, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Sharma performed 87,923 Medicare services across 2,985 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sharma received a total of $14,766 from 89 pharmaceutical and/or device companies across 876 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sharma is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in NJ
$14,766 industry payments
Medicare Practice Summary
Medicare Utilization ↗87,923
Medicare services
Top 12% in NJ for hematology & oncology
2,985
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,628 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
44,401 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 8,580 | $18 | $27 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
8,100 | $6 | $16 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
7,120 | $4 | $76 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,400 | $6 | $15 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,833 | $8 | $10 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
2,813 | $6 | $15 |
| Anti-nausea injection (ondansetron/Zofran) | 2,159 | $0 | $2 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,888 | $76 | $125 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,045 | $67 | $110 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
968 | $104 | $175 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
677 | $67 | $200 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
505 | $12 | $30 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
446 | $19 | $75 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
391 | $25 | $158 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
365 | $59 | $235 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
365 | $0 | $2 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
324 | $1 | $2 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
322 | $102 | $155 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
271 | $119 | $235 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
169 | $71 | $225 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
141 | $4 | $15 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
104 | $1 | $10 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
90 | $140 | $250 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
82 | $34 | $35 |
| Quadrivalent influenza vaccine, cell-culture derived A flu shot containing four strains of influenza virus, produced using cell culture technology rather than eggs. This formulation is free from preservatives and antibiotics. |
78 | $33 | $40 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
52 | $29 | $150 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
49 | $1 | $15 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
45 | $91 | $200 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
42 | $49 | $100 |
| 5% dextrose/water (500 ml = 1 unit) | 42 | $1 | $12 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
29 | $111 | $250 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
27 | $148 | $300 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.7% high complexity
86.3% medium
12.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,766
Total received (2018-2024)
Avg $2,109/year across 7 years
Top 18% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
89
Companies
876
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,152 (89.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,614 (10.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,537
2023
$2,338
2022
$2,445
2021
$2,530
2020
$1,644
2019
$2,292
2018
$1,980
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$237
SEAGEN INC.
$200
Bayer Healthcare Pharmaceuticals Inc.
$148
Merck Sharp & Dohme LLC
$128
PFIZER INC.
$115
BeiGene USA, Inc.
$109
Incyte Corporation
$102
AstraZeneca Pharmaceuticals LP
$89
Celgene Corporation
$84
Novartis Pharmaceuticals Corporation
$73
GENZYME CORPORATION
$67
SOBI, INC
$35
Blueprint Medicines Corporation
$34
Takeda Pharmaceuticals U.S.A., Inc.
$24
TAIHO ONCOLOGY, INC.
$23
Adaptive Biotechnologies Corporation
$20
PharmaEssentia USA Corporation
$18
Janssen Biotech, Inc.
$17
ARRAY BIOPHARMA INC
$16
Top 3 companies account for 38.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,487
Novartis Pharmaceuticals Corporation
$1,269
Amgen Inc.
$1,068
E.R. Squibb & Sons, L.L.C.
$937
Incyte Corporation
$657
Janssen Biotech, Inc.
$640
Seagen Inc.
$596
Celgene Corporation
$573
PFIZER INC.
$520
Merck Sharp & Dohme Corporation
$469
Bayer HealthCare Pharmaceuticals Inc.
$431
Merck Sharp & Dohme LLC
$399
Pharmacyclics LLC, An AbbVie Company
$319
GENZYME CORPORATION
$306
BeiGene USA, Inc.
$293
Genentech USA, Inc.
$273
Takeda Pharmaceuticals U.S.A., Inc.
$261
Lilly USA, LLC
$240
Bayer Healthcare Pharmaceuticals Inc.
$225
AVEO Pharmaceuticals, Inc.
$222
SEAGEN INC.
$200
Boehringer Ingelheim Pharmaceuticals, Inc.
$177
Astellas Pharma US Inc
$174
Eisai Inc.
$157
Seattle Genetics, Inc.
$145
PharmaEssentia USA Corporation
$100
Otsuka America Pharmaceutical, Inc.
$96
Teva Pharmaceuticals USA, Inc.
$96
Alexion Pharmaceuticals, Inc.
$94
GlaxoSmithKline, LLC.
$92
Regeneron Healthcare Solutions, Inc.
$87
Daiichi Sankyo Inc.
$87
CTI BioPharma Corp.
$85
JAZZ PHARMACEUTICALS INC.
$81
SANOFI-AVENTIS U.S. LLC
$77
Coherus Biosciences Inc.
$77
GE HEALTHCARE
$77
Jazz Pharmaceuticals Inc.
$72
Gilead Sciences, Inc.
$71
Kowa Pharmaceuticals America, Inc.
$70
Foundation Medicine, Inc.
$67
Blueprint Medicines Corporation
$65
Janssen Pharmaceuticals, Inc
$65
SERVIER PHARMACEUTICALS LLC
$64
Kite Pharma, Inc.
$58
Epizyme, Inc.,
$55
Puma Biotechnology, Inc.
$52
Adaptive Biotechnologies Corporation
$50
Myriad Genetic Laboratories, Inc.
$49
Pharmacyclics LLC, an AbbVie Company
$44
Sysmex Inostics Inc
$42
Rigel Pharmaceuticals, Inc.
$41
MorphoSys, US Inc.
$41
Mylan Institutional Inc.
$39
Stemline Therapeutics Inc.
$37
SOBI, INC
$35
Dova Pharmaceuticals
$34
Mirati Therapeutics, Inc.
$32
EMD Serono, Inc.
$31
Servier Pharmaceuticals LLC
$30
ARRAY BIOPHARMA INC
$30
MACROGENICS, INC.
$30
AbbVie, Inc.
$29
EISAI INC.
$28
AMAG Pharmaceuticals, Inc.
$27
AbbVie Inc.
$27
Karyopharm Therapeutics Inc.
$24
Sun Pharmaceutical Industries Inc.
$24
TAIHO ONCOLOGY, INC.
$23
Aveo Pharmaceuticals, Inc.
$21
Exelixis Inc.
$17
Spectrum Pharmaceuticals Inc.
$17
Cumberland Pharmaceuticals, Inc.
$16
Secura Bio, Inc.
$16
Myovant Sciences Inc.
$15
MEDIVATION FIELD SOLUTIONS LLC
$15
Janssen Scientific Affairs, LLC
$15
TG THERAPEUTICS, INC.
$15
TOLMAR Pharmaceuticals, Inc.
$15
TG Therapeutics, Inc.
$15
Collegium Pharmaceutical, Inc.
$15
SUN PHARMACEUTICAL INDUSTRIES INC.
$14
Alnylam Pharmaceuticals Inc.
$14
TESARO, Inc.
$14
Verastem, Inc.
$14
PORTOLA PHARMACEUTICALS, INC.
$14
Ipsen Biopharmaceuticals, Inc
$13
Radius Health, Inc.
$11
Sirtex Medical Inc
$6
Top 3 companies account for 25.9% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALUNBRIG · ANDEXXA · ASPARLAS · AYVAKIT · Abraxane · Alecensa · Avastin · BAVENCIO · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · ENHERTU · ERBITUX · ERLEADA · EVENITY · Enhertu · Erleada · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · Fulphila · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Livalo · MARGENZA · MEKINIST · MONJUVI · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Orserdu · PADCEV · PAXLOVID · PIQRAY · PRADAXA · PRECISETUMOR · PROMACTA · Perjeta · Pomalyst · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · SANCUSO · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SEGLENTIS · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SYNAGIS · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Trodelvy · Truxima · Tymlos · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTAMPZA · XTANDI · Xofigo · Xospata · Xtandi · YONSA · ZEJULA · ZEPOSIA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
431
Per 100K population
45.1
County median income
$123,715
Nearest hospital
RAMAPO RIDGE BEHAVIORAL HEALTH HOSPITAL
5.8 mi
5.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sharma is a mixed practice specialist, with above-average Medicare volume (top 12% in NJ), with low-engagement industry engagement in the top 18% of NJ peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sharma experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Sharma performed 44,401 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sharma receive payments from pharmaceutical companies?
Yes. Dr. Sharma received a total of $14,766 from 89 companies across 876 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sharma's costs compare to other hematology & oncology specialists in Mahwah?
Dr. Sharma's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sharma) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Mahwah
Browse hematology & oncology specialists in Mahwah ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology